Published in Cancer Sci on December 01, 2003
Retracted A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer. J Natl Cancer Inst (2008) 1.84
Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev (2008) 1.80
Retracted The oncopathic potency of Clostridium perfringens is independent of its alpha-toxin gene. Hum Gene Ther (2009) 1.70
Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics (2013) 1.44
Intermittent hypoxia effect on osteoclastogenesis stimulated by neuroblastoma cells. PLoS One (2014) 1.42
Identification of mRNAs that continue to associate with polysomes during hypoxia. RNA (2007) 1.35
Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun (2012) 1.30
In vivo and ex vivo epi-mode pump-probe imaging of melanin and microvasculature. Biomed Opt Express (2011) 1.19
Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells. Mol Pharm (2010) 1.07
Microenvironment and radiation therapy. Biomed Res Int (2012) 1.06
Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning. Cancer Cell Int (2011) 1.02
Imaging tumor oxyhemoglobin and deoxyhemoglobin concentrations with ultrasound-guided diffuse optical tomography. Technol Cancer Res Treat (2011) 1.02
Hyperbaric oxygen therapy for malignancy: a review. World J Surg (2006) 1.01
Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology. J Control Release (2011) 1.01
Quantitative magnetic resonance fluorine imaging: today and tomorrow. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 1.00
Curb challenges of the "Trojan Horse" approach: smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery. Adv Drug Deliv Rev (2013) 0.97
Digital switching of local arginine density in a genetically encoded self-assembled polypeptide nanoparticle controls cellular uptake. Nano Lett (2012) 0.97
Overexpression of MMP-9 and HIF-1α in Breast Cancer Cells under Hypoxic Conditions. J Breast Cancer (2011) 0.94
An update on antitumor activity of naturally occurring chalcones. Evid Based Complement Alternat Med (2013) 0.92
Microenvironments and cellular characteristics in the micro tumor cords of malignant solid tumors. Int J Mol Sci (2012) 0.91
Synthesis and structure-activity relationships of pteridine dione and trione monocarboxylate transporter 1 inhibitors. J Med Chem (2014) 0.90
Barriers to drug delivery in solid tumors. Tissue Barriers (2014) 0.89
Involvement of decreased hypoxia-inducible factor 1 activity and resultant G1-S cell cycle transition in radioresistance of perinecrotic tumor cells. Oncogene (2012) 0.88
Imaging tumor hypoxia by near-infrared fluorescence tomography. J Biomed Opt (2011) 0.88
Bacteriolytic therapy of experimental pancreatic carcinoma. World J Gastroenterol (2010) 0.85
Therapeutic potential of perineural invasion, hypoxia and desmoplasia in pancreatic cancer. Curr Pharm Des (2012) 0.84
Strategies To Assess Hypoxic/HIF-1-Active Cancer Cells for the Development of Innovative Radiation Therapy. Cancers (Basel) (2011) 0.84
Hypoxia/hepatoma dual specific suicide gene expression plasmid delivery using bio-reducible polymer for hepatocellular carcinoma therapy. J Control Release (2013) 0.83
eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer. Oncotarget (2015) 0.82
Rapid detection of hypoxia-inducible factor-1-active tumours: pretargeted imaging with a protein degrading in a mechanism similar to hypoxia-inducible factor-1alpha. Eur J Nucl Med Mol Imaging (2010) 0.82
Cancer drug delivery: considerations in the rational design of nanosized bioconjugates. Bioconjug Chem (2014) 0.81
Hypoxia-inducible factor-1α polymorphisms and risk of cancer metastasis: a meta-analysis. PLoS One (2013) 0.80
Hypoxia-inducible factor 1-mediated characteristic features of cancer cells for tumor radioresistance. J Radiat Res (2016) 0.80
Evaluation of p21 promoter for interleukin 12 radiation induced transcriptional targeting in a mouse tumor model. Mol Cancer (2013) 0.78
Azo-Based Iridium(III) Complexes as Multicolor Phosphorescent Probes to Detect Hypoxia in 3D Multicellular Tumor Spheroids. Sci Rep (2015) 0.78
Antiangiogenic effect of 2-benzoyl-phenoxy acetamide in EAT cell is mediated by HIF-1alpha and down regulation of VEGF of in-vivo. Invest New Drugs (2006) 0.78
Clostridial spores for cancer therapy: targeting solid tumour microenvironment. J Toxicol (2012) 0.78
Imaging and Targeting of the Hypoxia-inducible Factor 1-active Microenvironment. J Toxicol Pathol (2009) 0.78
Biophotonics techniques for structural and functional imaging, in vivo. Anal Cell Pathol (Amst) (2012) 0.77
Bacterial immunotherapy of gastrointestinal tumors. Langenbecks Arch Surg (2011) 0.76
Identification of novel hypoxia response genes in human glioma cell line a172. Iran J Basic Med Sci (2013) 0.75
Stable knockdown of CREB, HIF-1 and HIF-2 by replication-competent retroviruses abrogates the responses to hypoxia in hepatocellular carcinoma. Cancer Gene Ther (2016) 0.75
LY6E: a conductor of malignant tumor growth through modulation of the PTEN/PI3K/Akt/HIF-1 axis. Oncotarget (2016) 0.75
Hyperbaric oxygen as an adjunctive therapy in treatment of malignancies, including brain tumours. Med Oncol (2016) 0.75
Carbon-ion radiotherapy for locally advanced cervical cancer with bladder invasion. J Radiat Res (2016) 0.75
UCHL1-HIF-1 axis-mediated antioxidant property of cancer cells as a therapeutic target for radiosensitization. Sci Rep (2017) 0.75
Fluorescent/phosphorescent dual-emissive conjugated polymer dots for hypoxia bioimaging. Chem Sci (2015) 0.75
Hypoxic Modulation of HLA-G Expression through the Metabolic Sensor HIF-1 in Human Cancer Cells. J Immunol Res (2017) 0.75
Selective cytotoxicity of the anti-diabetic drug, metformin, in glucose-deprived chicken DT40 cells. PLoS One (2017) 0.75
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer (2004) 4.54
Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys (2005) 4.14
An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest (2004) 4.03
Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol (2007) 3.91
Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature (2009) 3.80
Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys (2010) 3.66
Thyroid gland tumor diagnosis at US elastography. Radiology (2005) 3.26
3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology (2002) 2.84
Cervical lymph node metastases: diagnosis at sonoelastography--initial experience. Radiology (2007) 2.56
Regional hyperthermia combined with radiotherapy for uterine cervical cancers: a multi-institutional prospective randomized trial of the international atomic energy agency. Int J Radiat Oncol Biol Phys (2005) 2.19
Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys (2008) 2.11
Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell (2003) 2.07
Distribution of lichen flora on South Korea. J Microbiol (2004) 1.98
Modified Dumon stent for the treatment of a bronchopleural fistula after pneumonectomy. Ann Thorac Surg (2003) 1.84
Vertebrate POLQ and POLbeta cooperate in base excision repair of oxidative DNA damage. Mol Cell (2006) 1.79
Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res (2007) 1.77
Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Proc Natl Acad Sci U S A (2011) 1.63
Collateral sprouting occurs following end-to-side neurorrhaphy. Plast Reconstr Surg (2004) 1.59
Characteristics of patients who developed radiation pneumonitis requiring steroid therapy after stereotactic irradiation for lung tumors. Cancer J (2006) 1.52
Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys (2002) 1.48
Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. Int J Radiat Oncol Biol Phys (2009) 1.47
Delayed initial radioactive iodine therapy resulted in poor survival in patients with metastatic differentiated thyroid carcinoma: a retrospective statistical analysis of 198 cases. J Nucl Med (2011) 1.45
CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res (2005) 1.44
Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys (2012) 1.43
Effects of antioxidants and NO on TNF-alpha-induced adhesion molecule expression in human pulmonary microvascular endothelial cells. Respir Med (2004) 1.41
A consensus-based guideline defining the clinical target volume for pelvic lymph nodes in external beam radiotherapy for uterine cervical cancer. Jpn J Clin Oncol (2010) 1.39
The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors. J Biol Chem (2008) 1.38
b-series Ganglioside deficiency exhibits no definite changes in the neurogenesis and the sensitivity to Fas-mediated apoptosis but impairs regeneration of the lesioned hypoglossal nerve. J Biol Chem (2001) 1.38
Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging (2005) 1.35
Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun (2012) 1.30
Development of a four-dimensional image-guided radiotherapy system with a gimbaled X-ray head. Int J Radiat Oncol Biol Phys (2006) 1.29
Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2010) 1.27
Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res (2002) 1.27
Cellular hypoxia of pancreatic beta-cells due to high levels of oxygen consumption for insulin secretion in vitro. J Biol Chem (2011) 1.27
The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochem Biophys Res Commun (2007) 1.22
Evaluation of lung injury after three-dimensional conformal stereotactic radiation therapy for solitary lung tumors: CT appearance. Radiology (2003) 1.20
Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol (2005) 1.17
An invasive adenocarcinoma of the accessory parotid gland: a rare example developing from a low-grade cribriform cystadenocarcinoma? Diagn Pathol (2011) 1.16
Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho. Int J Oncol (2006) 1.14
Interinstitutional variations in planning for stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys (2007) 1.14
Cholangitis and liver abscess after percutaneous ablation therapy for liver tumors: incidence and risk factors. J Vasc Interv Radiol (2003) 1.14
Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner. Proc Natl Acad Sci U S A (2011) 1.13
Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res (2009) 1.13
New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. Ann Surg (2002) 1.12
Characterization of FDG-PET images after stereotactic body radiation therapy for lung cancer. Radiother Oncol (2010) 1.12
Physiological mechanisms of regulating alloimmunity: cytokines, CTLA-4, CD25+ cells, and the alloreactive T cell clone size. J Immunol (2002) 1.12
Early protective effect of bone marrow mononuclear cells against ischemic white matter damage through augmentation of cerebral blood flow. Stroke (2010) 1.11
Evaluation of mass-like consolidation after stereotactic body radiation therapy for lung tumors. Int J Clin Oncol (2007) 1.11
Direct targeting of fibroblast growth factor-inducible 14 protein protects against renal ischemia reperfusion injury. Kidney Int (2010) 1.11
Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome. Mol Immunol (2013) 1.10
Evaluation of primary brain tumors with FLT-PET: usefulness and limitations. Clin Nucl Med (2006) 1.10
Postoperative radiotherapy for intracranial ependymoma: analysis of prognostic factors and patterns of failure. J Neurooncol (2002) 1.10
Inhibition of transcellular tumor cell migration and metastasis by novel carba-derivatives of cyclic phosphatidic acid. Biochim Biophys Acta (2006) 1.10
Dosimetric verification in participating institutions in a stereotactic body radiotherapy trial for stage I non-small cell lung cancer: Japan clinical oncology group trial (JCOG0403). Phys Med Biol (2006) 1.10
Downregulation of c-MYC protein levels contributes to cancer cell survival under dual deficiency of oxygen and glucose. Cancer Res (2010) 1.08
General rules for clinical and pathological recording of breast cancer 2005. Breast Cancer (2005) 1.08
Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2). Int J Radiat Oncol Biol Phys (2011) 1.07
Preclinical readiness testing of the Arrow International CorAide left ventricular assist system. Ann Thorac Surg (2004) 1.06
Microenvironment and radiation therapy. Biomed Res Int (2012) 1.06
CD70 signaling is critical for CD28-independent CD8+ T cell-mediated alloimmune responses in vivo. J Immunol (2005) 1.06
Mandibular fractures treated with maxillomandibular fixation screws (MMFS method). J Craniofac Surg (2006) 1.05
Blocking CD147 induces cell death in cancer cells through impairment of glycolytic energy metabolism. Biochem Biophys Res Commun (2008) 1.05
Alveolar adenoma of the lung: computed tomography and magnetic resonance imaging findings. J Thorac Imaging (2002) 1.04
Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. Mod Rheumatol (2010) 1.04
TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci (2008) 1.04
Suppression of VEGF transcription in renal cell carcinoma cells by pyrrole-imidazole hairpin polyamides targeting the hypoxia responsive element. Acta Oncol (2006) 1.04
Outcome of percutaneous transhepatic venoplasty for hepatic venous outflow obstruction after living donor liver transplantation. Radiology (2006) 1.03
The HIF-1-active microenvironment: an environmental target for cancer therapy. Adv Drug Deliv Rev (2009) 1.03
Local hyperthermia combined with external irradiation for regional recurrent breast carcinoma. Int J Clin Oncol (2004) 1.02
18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy. Ann Nucl Med (2004) 1.01
Hydrogen sulfide inhibits hypoxia- but not anoxia-induced hypoxia-inducible factor 1 activation in a von hippel-lindau- and mitochondria-dependent manner. Antioxid Redox Signal (2011) 1.00
Treatment planning of stereotactic radiotherapy for solitary lung tumor. Int J Radiat Oncol Biol Phys (2005) 1.00
Early sensitization to house dust mite is a major risk factor for subsequent development of bronchial asthma in Japanese infants with atopic dermatitis: results of a 4-year followup study. Ann Allergy Asthma Immunol (2002) 1.00
Transthoracic percutaneous radiofrequency ablation for liver tumors in the hepatic dome. J Vasc Interv Radiol (2004) 1.00
A case of pregnancy-induced thrombotic thrombocytopenic purpura with a kidney allograft recipient. Clin Transplant (2010) 1.00
IL12RB2 and ABCA1 genes are associated with susceptibility to radiation dermatitis. Clin Cancer Res (2008) 0.99
Near-infrared fluorescence tumor imaging using nanocarrier composed of poly(L-lactic acid)-block-poly(sarcosine) amphiphilic polydepsipeptide. Biomaterials (2009) 0.98
Near-infrared fluorescent labeled peptosome for application to cancer imaging. Bioconjug Chem (2007) 0.98
Cytological features of cystadenocarcinoma in cyst fluid of the parotid gland: Diagnostic pitfalls and literature review. Diagn Cytopathol (2010) 0.98
Inactivation of Rho GTPases by p190 RhoGAP reduces human pancreatic cancer cell invasion and metastasis. Cancer Sci (2006) 0.98
Suppression of the invasive capacity of rat ascites hepatoma cells by knockdown of Slingshot or LIM kinase. J Biol Chem (2008) 0.98
A novel screen using the Reck tumor suppressor gene promoter detects both conventional and metastasis-suppressing anticancer drugs. Oncotarget (2010) 0.97
In vivo imaging of HIF-active tumors by an oxygen-dependent degradation protein probe with an interchangeable labeling system. PLoS One (2010) 0.97
Histiocytic sarcoma of the parotid gland region. Pathol Int (2011) 0.97
Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor. Clin Exp Metastasis (2003) 0.96
Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arterioscler Thromb Vasc Biol (2002) 0.96
Real-time imaging of hypoxia-inducible factor-1 activity in tumor xenografts. J Radiat Res (2005) 0.96
Requirements for induction and maintenance of peripheral tolerance in stringent allograft models. Proc Natl Acad Sci U S A (2005) 0.96
Trends in local therapy application for early breast cancer patients in the Japanese Breast Cancer Society Breast Cancer Registry during 2004-2009. Breast Cancer (2012) 0.96
Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy. Pediatr Int (2002) 0.96
A consensus-based guideline defining clinical target volume for primary disease in external beam radiotherapy for intact uterine cervical cancer. Jpn J Clin Oncol (2011) 0.95
Long-term follow-up of a randomized Phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer (KROSG0101/JROSG021). Jpn J Clin Oncol (2012) 0.95
Bilateral breast-conserving therapy for bilateral breast cancer: results and consideration of radiation technique. Breast Cancer (2005) 0.95
Early reduction of glucose uptake after cisplatin treatment is a marker of cisplatin sensitivity in ovarian cancer. Cancer Sci (2010) 0.95